In models of AD, both topical application and oral supplementation with EGCG reduced eosinophil and mast-cell infiltration in the skin, decreased IL-4 and thymic stromal lymphopoietin (TSLP) production, and improved skin-barrier integrity [24,176,177]. This evidence concerns the gene TSLP and Alzheimer disease.